Mustang Bio: Clinical Trials

3 trials sponsored by Mustang Bio, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 active not recruiting. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Terminated 2, Active not recruiting 1
Phase 23Terminated 2, Active not recruiting 1

Follow Mustang Bio: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent
Phase 1 / Phase 2TerminatedMustang Bio202022-05-242024-07-22
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2TerminatedMustang Bio32020-02-172024-07-22
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 1 / Phase 2Active not recruitingFred Hutchinson Cancer Center532017-12-052026-06-22

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Recurrence (1)

Interventions

Cyclophosphamide (2)  ·  fludarabine phosphate (2)  ·  Immunotherapy, Adoptive (1)  ·  Leukapheresis (1)  ·  fludarabine (1)  ·  relmapirazin (1)

Countries

United States (3)

Top investigators

Lihua E Budde, MD (1)  ·  Mazyar Shadman (1)  ·  Mazyar Shadman, MD (1)

Results publications

PMID 34515338

NIH funding

R44CA265616 (1)